Hjem › Akut myeloid leukæmi › Kansas
Akut myeloid leukæmi kliniske forsøg i Kansas
20 studier for Akut myeloid leukæmi søger deltagere på steder i Kansas.
Byer i Kansas
Officiel studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- og 4 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- og 1 flere
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- og 7 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- og 2 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- og 1 flere
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Kansas City KS-KUMC, Fairway
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Kansas City KS-KUMC, Kansas City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- og 1 flere
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 25. aug. 2026 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- The University of Kansas Cancer Center, Kansas City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Kansas Cancer Center, Westwood
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 17. jul. 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Kansas, Westwood
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- University of Kansas Medical Center Research Institute, Inc., Kansas City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06146257Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- University of Kansas Cancer Center, Westwood
RekruttererFase 1
Alder 18 til 65 · Alle køn · Opdateret 25. mar. 2026 · NCT03533816A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Kansas Medical Center, Westwood
RekruttererFase 2
Alder 18 til 66 · Alle køn · Opdateret 17. mar. 2026 · NCT06859424A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- The University of Kansas Medical Center Research Institute, Fairway
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184Safety of MT-401-OTS in Patients With Relapsed AML or MDS
- KU Cancer Center, Kansas City
RekruttererFase 1
Alder 65 og opefter · Alle køn · Opdateret 16. dec. 2025 · NCT06552416APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- University of Kansas, Fairway
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. maj 2025 · NCT06634394Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- University of Kansas Cancer Center, Fairway
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. mar. 2025 · NCT02781883Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
- University of Kansas Cancer Center, Fairway
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. jun. 2020 · NCT04167696Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.